SCYL1BP1 has Tumor-suppressive Functions in Human Lung Squamous Carcinoma Cells by Regulating Degradation of MDM2

  • Yang, Zhi-Ping (Department of Oncology and Pathology, The First Hospital of Jiaxing) ;
  • Xie, Yong-Hong (Department of Pathology, Jiaxing University College of Medicine) ;
  • Ling, Dan-Yan (Shanghai Emay Biotechnologies Co., Ltd.) ;
  • Li, Jin-Rui (Department of Oncology and Pathology, The First Hospital of Jiaxing) ;
  • Jiang, Jin (Department of Oncology and Pathology, The First Hospital of Jiaxing) ;
  • Fan, Yao-Hua (Department of Oncology and Pathology, The First Hospital of Jiaxing) ;
  • Zheng, Jia-Lian (Department of Oncology and Pathology, The First Hospital of Jiaxing) ;
  • Wu, Wan-Xin (Department of Oncology and Pathology, The First Hospital of Jiaxing)
  • Published : 2014.09.15


SCY1-like 1-binding protein 1 (SCYL1BP1) is a newly identified transcriptional activator domain containing protein with many unknown biological functions. Recently emerging evidence has revealed that it is a novel regulator of the p53 pathway, which is very important for the development of human cancer. However, the effects of SCYL1BP1 on human lung squamous carcinoma cell biological behavior remain poorly understood. In this study, we present evidence that SCYL1BP1 can promote the degradation of MDM2 protein and further inhibit the G1/S transition of lung squamous carcinoma cell lines. Functional assays found that reintroduction of SCYL1BP1 into lung squamous carcinoma cell lines significantly inhibited cell proliferation, migration, invasion and tumor formation in nude mice, suggesting strong tumor suppressive function of SCYL1BP1 in lung squamous carcinoma. Taken together, our data suggest that the interaction of SCYL1BP1/MDM2 could accelerate MDM2 degradation, and may function as an important tumor suppressor in lung squamous carcinomas.


Supported by : Zhejiang province


  1. Bexiga MG, Simpson JC (2013). Human diseases associated with form and function of the Golgi complex. Int J Mol Sci, 14, 18670-81.
  2. Brooks CL, Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell, 21, 307-15.
  3. Chansaenroj J, Theamboonlers A, Junyangdikul P, et al (2013). Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566) genes in Thai cervical cancer patients with HPV 16 infection. Asian Pac J Cancer Prev, 14, 341-6.
  4. Cordon-Cardo C, Latres E, Drobnjak M, et al (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res, 54, 794-9.
  5. Di Y, Li J, Fang J, et al (2003). Cloning and characterization of a novel gene which encodes a protein interacting with the mitosis-associated kinase-like protein NTKL. J Hum Genet, 48, 315-21.
  6. Grossman SR, Perez M, Kung AL, et al (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell, 2, 405-15.
  7. Hennies HC, Kornak U, Zhang H, et al (2008). Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet, 40, 1410-2.
  8. Hu L, Liu M, Chen L, et al (2012). SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma. Carcinogenesis, 33, 1581-8.
  9. Huang H, Tindall DJ (2011). Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta, 1813, 1961-4.
  10. Hwang-Verslues WW, Chang PH, Wei PC, et al (2011). miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene, 30, 2463-74.
  11. Jackson PK, Eldridge AG, Freed E, et al (2000). The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol, 10, 429-39.
  12. Kang DS, Tian X, Benovic JL (2014). Role of beta-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr Opin Cell Biol, 27, 63-71.
  13. Legube G, Linares LK, Lemercier C, et al (2002). Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J, 21, 1704-12.
  14. Li W, Zheng J, Deng J, et al (2014). Increased levels of the long intergenic non-protein coding RNA POU3F3 promote DNA methylation in esophageal squamous cell carcinoma cells. Gastroenterology, 146, 1714-26
  15. Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
  16. Liu Y, Chen Y, Lu X, et al (2012). SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway. Mol Biol Cell, 23, 4506-14.
  17. Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6.
  18. Manfredi JJ (2010). The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev, 24, 1580-9.
  19. Martinez J, Georgoff I, Levine AJ (1991). Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev, 5, 151-9.
  20. Momand J, Zambetti GP, Olson DC, et al (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-45.
  21. Polyak K, Lee MH, Erdjument-Bromage H, et al (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
  22. Sczaniecka M, Gladstone K, Pettersson S, et al (2012). MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem, 287, 14052-68.
  23. Shenoy SK, McDonald PH, Kohout TA, et al (2001). Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science, 294, 1307-13.
  24. Sparks A, Dayal S, Das J, et al (2013). The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. Oncogene, [Epub ahead of print].
  25. Uldrijan S, Pannekoek WJ, Vousden KH (2007). An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J, 26, 102-12.
  26. van der Laan S, Tsanov N, Crozet C, et al (2013). High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency. Mol Cell, 52, 366-79.
  27. Wade M, Li YC, Wahl GM (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer, 13, 83-96.
  28. Wang SP, Wang WL, Chang YL, et al (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol, 11, 694-704.
  29. Yan J, Di Y, Shi H, et al (2010a). Overexpression of SCYL1-BP1 stabilizes functional p53 by suppressing MDM2-mediated ubiquitination. FEBS Lett, 584, 4319-24.
  30. Yan J, Zhang D, Di Y, et al (2010b). A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination. FEBS Lett, 584, 3275-8.
  31. Yogosawa S, Miyauchi Y, Honda R, et al (2003). Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochem Biophys Res Commun, 302, 869-72.
  32. Zheng J, Deng J, Xiao M, et al (2013). A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. Cancer Res, 73, 5151-62.
  33. Zheng J, Jiang L, Zhang L, et al (2012). Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. Carcinogenesis, 33, 2409-16.
  34. Zhou J, Wang W (2011). Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol, 104, 278-83.

Cited by

  1. Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes vol.58, pp.6, 2015,